New Study Findings from Division of Pharmacotherapy and Experimental Therapeutics Illuminate Research in Platelet Aggregation Inhibitors (CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With...).

A new study conducted by the Division of Pharmacotherapy and Experimental Therapeutics has found that Black patients treated with the antiplatelet agent clopidogrel after percutaneous coronary intervention (PCI) have an increased risk of adverse cardiovascular outcomes. The study examined the impact of the CYP2C19 genotype on cardiovascular outcomes in Black patients and found that those with intermediate and poor metabolizer phenotypes had higher rates of major atherothrombotic events compared to patients without a no function allele. The study suggests that further research is needed to determine if genotype-guided use of other medications can improve outcomes for Black patients undergoing PCI. [Extracted from the article]